Call for Late Breakers CLOSED

Abstracts containing novel data, not available at the time of the original abstract submission deadline, will be considered under the category of “Late Breaker.” Only submissions containing the most current, cutting-edge science will be selected.

Abstract Submission Opens 31 January 2018
Abstract Submission Deadline CLOSED
Late Breaker Abstracts Opens 27 July 2018
Late Breaker Abstracts Deadline CLOSED

Submission Guidelines and Policies

Submission Topics
  • Antibody functions (neutralizing and non-neutralizing)
  • Antiretroviral resistance and impact on prevention
  • Behavioral and social science research
  • Cellular immunity
  • Clinical trial results
  • Community engagement in prevention research
  • Contraception, pregnancy and HIV prevention
  • Correlates of protection and exposure
  • Delivery technologies: novel approaches, formulation and multi-purpose
  • Discovery and evaluation of biomedical agents
  • Epidemiology of HIV
  • Ethics in HIV prevention research
  • Immunogenetics (host immunity and restriction factors)
  • Implementation science, including structural interventions, PrEP & VMMC
  • Innate immunity
  • Mathematical modeling: impact and effectiveness
  • Microbiome & STI: impact on prevention
  • Mucosal immunology
  • Novel vaccine and prevention approaches
  • Passive immunization
  • Pharmacology/PK and PD studies
  • Phylogenetics and viral diversity
  • Policy and advocacy
  • Preclinical studies for HIV prevention
  • Product acceptability and adherence
  • Systems immunobiology approaches & sequencing technologies
  • Therapeutic vaccine, viral latency and cure
  • Transmission of HIV
  • Treatment as prevention
Abstract Guidelines

Abstract titles: Titles should be entered in Title Case. Title case has a capital letter for the start of principal words. Do not use capital letters for prepositions, articles or conjunctions unless they start the title.

Abstract text: Abstracts should be divided in sections when submitted (background, methods, results and conclusion). Do not include section titles in the abstract text, they will be automatically inserted during the production of the abstract books. The cumulative character count of all four sections is limited to 2,000 characters total, including spaces. You may copy text from your text editing program into the relevant abstract section. Please note that special characters and formats may be lost during the pasting process, we recommend using "Arial" in your text editor before copying to reduce any errors. Please check your abstract during the Preview and edit if necessary.  No tables or graphics are allowed.

Authors: You may list up to 20 authors on your abstract.

Selection Process

Submitted abstracts are assigned for peer review by the conference organizers and are reviewed by members of the Abstract Review Committee, that includes the Program Organizing Committee and other external reviewers. To minimize subjectivity in the scoring process, any reviewer with a conflict of interest (as defined by NIH rules, e.g., co-authorship, financial interest, or scientific/personal conflict with the authors that could affect objectivity of scoring) is excluded from scoring or discussing the abstract in question.

Abstracts will be scored based on the following scale:

  • 1 - Recommend for oral presentation
  • 2 - Potential oral presentation
  • 3 - Recommend for poster presentation
  • 4 - Potential poster presentation
  • 5 - Rejection

In the final rankings, mean score and standard deviation are calculated, and the reviewers' scores will be anonymous. Abstract acceptance is based upon abstract quality, the potential significance of the observations, and the rigor with which the scientific methods were applied. Further, the Program Organizing Committee considers thematic balance in determining abstract assignments.

Acceptance of Abstracts

Compliance with all stated conditions including adherence to the deadline is required. Acknowledgement of receipt of completed abstracts will be sent via email upon submission.

The Program Organizing Committee reserves the right to determine acceptance of an abstract and the right to determine the presentation form. The conference secretariat will notify late breaker abstract submission authors of acceptance and form of presentation on 12 September 2018.

Individuals submitting abstracts agree that if their abstract is accepted, they will attend the HIVR4P 2018 conference and present their abstract as scheduled. Presenting authors must register no later than 19 September 2018. Unregistered presenters after this date will be removed from the conference proceedings.

The presenting author should be prepared to answer substantive questions about all aspects of the data. If a change in the presenters’ ability to participate occurs, the presenter is asked to contact the conference secretariat immediately at [email protected].

Abstract Publication

Accepted abstracts will be included in the HIVR4P electronic and printed conference materials and as an open access online supplement in a scientific journal. More information will be made available soon.


By submitting an abstract, authors and co-authors transfer any copyrights and grant permission to HIVR4P to publish the abstract(s) as noted above. Abstracts will not be published or made public prior to the start of the conference.

Webcasting and Archiving Presentation Slides

All conference sessions will be recorded and webcast. Presenters will be given the opportunity to remove specific slides from their presentations prior to posting on the meeting website. Posting of the presentation audio is mandatory with the acceptance to give an oral presentation. This arrangement is necessary because the concurrent sessions of the meeting prevent participants from attending all talks of interest.


All research presented at HIVR4P 2018 is embargoed until the conclusion of the study’s presentation at the conference. Embargoes apply to all forms of dissemination of research news, including press releases, published media interviews, and social media dissemination. All HIVR4P participants, including research sponsors, presenters and attendees, are required to follow the conference embargo policy.

Please direct any inquiries about the HIVR4P 2018 embargo policy to Mark Aurigemma at [email protected].



For any inquiries, please contact [email protected]. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.

Conference News


Subscribe to the Newsletter to receive important information about the upcoming Conference.